MedTrace Logo

Bacteriophage Cocktail Therapy for Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia

NCT07202234 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 248

Last updated 2025-10-01

No results posted yet for this study

Summary

The purpose of this study is to systematically evaluate the efficacy and safety of bacteriophage cocktail therapy in patients with ventilator-associated pneumonia caused by Gram-negative bacterial infections.

Conditions

  • VAP - Ventilator Associated Pneumonia

Interventions

DRUG

Phage cocktail administered via nebulization

Phage cocktail administered via nebulization，BID

DRUG

Nebulized normal saline inhalation therapy

Nebulized normal saline inhalation therapy, BID

Sponsors & Collaborators

  • Peking University Third Hospital

    collaborator OTHER

  • Zhengzhou Central Hospital

    collaborator OTHER

  • Henan Provincial People's Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • The 8th medical center of chinese PLA general hospital

    collaborator UNKNOWN

  • The First Medical Center of Chinese PLA General Hospital

    collaborator OTHER

  • Chinese PLA General Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2028-05-31
Completion
2028-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07202234 on ClinicalTrials.gov